ES2155134T3 - Derivados de imidazolidina y su utilizacion. - Google Patents

Derivados de imidazolidina y su utilizacion.

Info

Publication number
ES2155134T3
ES2155134T3 ES95926500T ES95926500T ES2155134T3 ES 2155134 T3 ES2155134 T3 ES 2155134T3 ES 95926500 T ES95926500 T ES 95926500T ES 95926500 T ES95926500 T ES 95926500T ES 2155134 T3 ES2155134 T3 ES 2155134T3
Authority
ES
Spain
Prior art keywords
rent
alquilpiperazinil
sterified
ceno
oalquenilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926500T
Other languages
English (en)
Inventor
Harukazu Fukami
Motoo Sumida
Shinjiro Niwata
Saki Kakutani
Masayuki Saitoh
Hiroshi Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2155134T3 publication Critical patent/ES2155134T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

DERIVADO DE IMIDAZOLIDINA REPRESENTADO POR LA FORMULA GENERAL (I) Y MEDICINAS QUE LO CONTIENEN COMO EL INGREDIENTE ACTIVO, EJEMPLOS REPRESENTATIVOS QUE INCLUYEN UN INHIBIDOR DE QUIMASA Y UN PREVENTIVO O REMEDIO PARA ENFERMEDADES CIRCULATORIAS O CARDIACAS CAUSADAS POR PALPITACIONES ANORMALES INDUCIDAS POR LA ANGIOTENSINA II, DONDE A Y B REPRESENTAN CADA UNO UN GRUPO DE HIDROCARBURO AROMATICO QUE PUEDE SER SUSTITUIDO POR UNO O MAS SUSTITUYENTES SELECCIONADOS DE ENTRE HALOGENO, C ALQUILO, ALCOXI, ALQUILENODIOXI, FENOXI, NITRO,CIANO, FENILO, ALCANOILAMINO, CARBOXILO QUE PUEDE SER ESTERIFICADO CON ALQUILO O ALQUENILO, CARBOXIALQUILO QUE PUEDE SER ESTERIFICADO CON ALQUILO O ALQUENILO, CARBOXIALQUILOXI QUE SER ESTERIFICADO CON ALQUILO OALQUENILO, N-ALQUILPIPERAZINIL CARBONILO, N-ALQUILPIPERAZINIL-CARBONIALQUILO, N-ALQUILOPIPERAZINIL-CARBONILALQUILOXI Y MORFOLINOCARBONILO; X REPRESENTA OXIGENO O SULFURO.
ES95926500T 1994-07-29 1995-07-26 Derivados de imidazolidina y su utilizacion. Expired - Lifetime ES2155134T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20786794 1994-07-29
JP33370694 1994-12-07

Publications (1)

Publication Number Publication Date
ES2155134T3 true ES2155134T3 (es) 2001-05-01

Family

ID=26516513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926500T Expired - Lifetime ES2155134T3 (es) 1994-07-29 1995-07-26 Derivados de imidazolidina y su utilizacion.

Country Status (7)

Country Link
US (1) US5691335A (es)
EP (1) EP0721944B1 (es)
AT (1) ATE198743T1 (es)
AU (1) AU3086095A (es)
DE (1) DE69519921T2 (es)
ES (1) ES2155134T3 (es)
WO (1) WO1996004248A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912261A (en) * 1994-12-20 1999-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Carboxyalkyl heterocyclic derivatives
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
JPH10182460A (ja) * 1996-12-27 1998-07-07 Nippon Zoki Pharmaceut Co Ltd ３−デオキシグルコソン生成阻害剤
US20050267148A1 (en) * 1998-07-15 2005-12-01 Teijin Limited Benzimidazole derivative
PL203730B1 (pl) 1998-07-15 2009-11-30 Teijin Ltd Pochodna tiobenzimidazolu, kompozycja farmaceutyczna i jej zastosowanie
KR100381214B1 (ko) * 1998-08-10 2003-09-22 주식회사 엘지생명과학 항암제로유용한이미다졸리딘-2,4-디온유도체및그의제조방법
CA2341195A1 (en) * 1998-08-20 2000-03-02 Mitsunori Waki Prophylactic or therapeutic composition for ocular circulation disorders
ATE326451T1 (de) * 1998-08-21 2006-06-15 Daiichi Asubio Pharma Co Ltd Chinazolin derivate und therapeutische verwendungen davon
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
US6432978B1 (en) * 1998-12-01 2002-08-13 Meiji Seika Kaisha, Ltd. SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities
WO2001030388A1 (en) * 1999-10-25 2001-05-03 Senju Pharmaceutical Co., Ltd. Tension-relieving agents for ciliary muscle
HUP0104952A3 (en) 1999-11-01 2006-02-28 Daiichi Asubio Pharma Co Ltd Inhibitors against vascular lipid deposition containing chymase-inhibiting substances
US6300503B1 (en) * 1999-12-17 2001-10-09 Dixie Chemical Company Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
DE60126199T2 (de) 2000-02-22 2008-02-28 Asubio Pharma Co., Ltd. Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktive bestandteile
EP1192950B1 (en) 2000-02-22 2006-07-26 Daiichi Asubio Pharma Co., Ltd. Therapeutic drugs for dermatitis exhibiting a biphasic skin reaction containing chymase inhibitors as the active ingredient
CN1366461A (zh) 2000-02-22 2002-08-28 三得利株式会社 含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物
JP4711523B2 (ja) 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
US6919365B2 (en) * 2001-04-11 2005-07-19 Senju Pharmaceutical Co., Ltd. Imidazolidinedione derivatives and use thereof as drugs
RU2005105340A (ru) * 2002-07-30 2005-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик, С.А.С. (Fr) Применение ингибиторов химазы для предотвращения или лечения повреждения артериовенозных имплантатов
FR2845383B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845384B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
CA2500977A1 (en) * 2002-10-04 2004-04-15 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof in therapeutics
CN100477995C (zh) 2003-05-09 2009-04-15 东丽株式会社 增强剂
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
US7361767B2 (en) * 2003-11-14 2008-04-22 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7544756B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
EP2391624B1 (en) 2009-01-30 2013-01-16 Boehringer Ingelheim International GmbH Azaquinazolinediones useful as chymase inhibitors
HUE037389T2 (hu) 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CA3105575A1 (en) 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
HK1224288A1 (zh) * 2013-11-08 2017-08-18 Bayer Pharma Aktiengesellschaft 作为类糜蛋白酶抑制剂的取代的尿嘧啶
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3468952B1 (en) * 2016-06-14 2020-11-25 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
KR102384668B1 (ko) * 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
US11236053B2 (en) 2017-07-26 2022-02-01 Emory University NADPH oxidase inhibitors and uses thereof
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1207391B (de) * 1962-05-30 1965-12-23 Degussa Verfahren zur Herstellung von 3-Benzoyl-5, 5-dimethylhydantoinen
US4166124A (en) * 1970-05-15 1979-08-28 U.S. Philips Corporation Insecticidal 2,6-dihalobenzoyl urea derivatives
JPS5371073A (en) * 1976-12-03 1978-06-24 Sumitomo Chem Co Ltd 1-cyclic alkyl carbonyl-3(3,5-dihalogenophenyl)hydantoin derivs., process fo r their preparation and fungicides for agriculture and horti culture contg. the same as active constituents
JPS5855468A (ja) * 1981-09-25 1983-04-01 Sumitomo Chem Co Ltd ５−クロロヒダントイン誘導体、その製造法およびそれを有効成分として含有する殺虫剤
US4474796A (en) * 1983-02-04 1984-10-02 Sumitomo Chemical Company, Limited Insecticidal substituted hydantoins
JPH068281B2 (ja) * 1985-09-19 1994-02-02 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とするアルド−スレダクタ−ゼ阻害剤

Also Published As

Publication number Publication date
ATE198743T1 (de) 2001-02-15
DE69519921D1 (de) 2001-02-22
DE69519921T2 (de) 2001-06-13
EP0721944A4 (en) 1997-01-02
US5691335A (en) 1997-11-25
AU3086095A (en) 1996-03-04
WO1996004248A1 (en) 1996-02-15
EP0721944B1 (en) 2001-01-17
EP0721944A1 (en) 1996-07-17

Similar Documents

Publication Publication Date Title
ES2155134T3 (es) Derivados de imidazolidina y su utilizacion.
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
ES2164889T3 (es) Semicarbazonas con actividad sobre el snc y preparados farmaceuticos a base de las mismas.
ES2138971T3 (es) Regulador de la apoptosis.
MX9202747A (es) Nuevas sulfonamidas y procedimientos para su preparacion.
ES2190430T3 (es) Nuevas sulfonamidas.
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
DK254787D0 (da) Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2190081T3 (es) Derivados del triazol, un procedimiento para su preparacion y los medicamentos que los contienen.
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
ES2038074A1 (es) Nuevos derivados de benzimidazol, su preparacion y su aplicacion como medicamentos.
ATE39357T1 (de) Derivate von griseolicsaeure und ihre verwendung.
ECSP930949A (es) Derivados de 2- imidazolina -5- onas y 2- imidazolina- 5 tionas fungicidas
ES2076894B1 (es) Derivados de 2-(4-(4-azolilbutil)-1-piperacinil)-5-hidroxipirimidina, su preparacion y su aplicacion como medicamentos.
ES2103825T3 (es) Composiciones farmaceuticas que contienen 5-difluorometoxi-2-(3,4-dimetoxi-2-piridil)-metilsulfinil)bencimidazol y un agente anti-helicobacter para el tratamiento de trastornos gastrointestinales.
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
ES2099865T3 (es) Ciclopentanoperhidrofenantreno-17beta-(3-furil)-3-derivados y composiciones farmaceuticas que comprenden los mismos para el tratamiento de trastornos cardiovasculares.
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 721944

Country of ref document: ES